You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科興製藥(688136.SH):與邁博太科簽署協議 獲CMAB008於合作區域獨家商業化許可
格隆匯 06-29 20:19

格隆匯6月29日丨科興製藥(688136.SH)公佈,公司於2021年6月28日與泰州邁博太科藥業有限公司(“邁博太科”)簽署《CMAB008國際獨家商業化許可協議》(“框架協議”),授予公司就CMAB008在全球除中國大陸、日本、歐洲、北美洲外的所有國家和地區(“合作區域”)獨家商業化許可。

合作區域全部或者部分國家或地區的獨家代理許可之生效,以公司與邁博太科達成的許可生效區域獨家代理協議約定之許可費的支付為條件。(此等符合條件的合作區域以下簡稱“許可生效區域”)。

公司與邁博太科就CMAB008產品合作區域獨家代理商業化許可洽談合作。公司負責許可生效區域CMAB008的商業化,邁博太科負責CMAB008的生產及提供合作區域註冊資料等。

CMAB008為一種重組抗TNF-alpha嵌合單克隆抗體,是用於治療類風濕關節炎、成人及兒童克羅恩病、瘻管性克羅恩病、強直性脊柱炎、銀屑病及成人潰瘍性結腸炎的英夫利西單抗生物類似藥,預計2021年取得中國大陸的藥品上市許可。

該次合作引進商業化階段的抗體藥物,將有助於公司進一步擴展產品管線,為尚未滿足的臨牀需求提供治療選擇,從而進一步完善公司市場佈局。同時,也為未來自主研發或引入的產品奠定海外銷售基礎,有利於增加海外營銷渠道、擴大海外營銷規模,提升公司的國際影響力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account